Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC

NCT05414032 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT05414032
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05414032 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC
Lead sponsor
University Health Network, Toronto
Phase
Phase 2
Overall status
Recruiting
Start date
July 12, 2023
Completion date
July 31, 2028
Enrollment
102 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locoregionally advanced head and neck squamous cell carcinoma (la-hnscc)